BacAlt Biosciences 
Dealstreet

JSA, White & Brief act on BacAlt Biosciences fundraise

BacAlt develops sustainable alternatives to conventional specialty ingredients by producing biopolymers from agro-industrial waste.

Bar & Bench

Bacalt BioSciences Private Limited has raised ₹18 crore from a fundraise led by Avaana Sustainability Fund.

White & Brief advised BacAlt on this fundraise.

The transaction team was led by Arvind Gurumurthy (Senior Partner).

JSA Advocates & Solicitors acted as legal advisor to lead investor Avaana Sustainability Fund. The Firm provided end-to-end legal support, including conducting due diligence on BacAlt, drafting, negotiating and finalizing transaction documents, and assisting with closing actions.

The transaction was led by Siddharth Mody (Lead Partner). He was supported by Anurag Shrivastav (Partner), Associates Shefalika Shekhawat, Gavin Perereia, and Prakhar Jain.

Siddharth Mody, Anurag Shrivastav

Founded in 2023 by Shruti Kutmutia and Pranav Nair, BacAlt is a Bangalore-based start-up that develops sustainable alternatives to conventional specialty ingredients by producing biopolymers from agro-industrial waste through advanced bio-manufacturing processes.

The funding round, which also saw participation from Lubrizol Advanced Materials Europe BV, raised primary capital infusion, which Bacalt intends to deploy to scale its R&D processes, establish pilot production facilities, expand its team, and develop go-to-market strategies for international expansion.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

Supreme Court asks Centre to consider framing rules to regulate social media accounts of minors

Karnataka HC quashes FIR against BJP's Chalavadi Narayanaswamy, TS Srivatsa over remarks about ST status to Kurubas

Collegium recommends 3 new judges for Supreme Court

Delhi High Court to decide personality rights cases of 3 celebrities together

Kerala High Court invokes Mammooty's 1994 movie, says plight of cancer patients remains unchanged

SCROLL FOR NEXT